Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Better Therapeutics, Inc.BTTX · Entity 94385 | Director | December 18, 2023 | December 20, 2023 |
| California BanCorp \ CABCAL · Entity 5250 | Director | August 20, 2026 | August 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Better Therapeutics, Inc.
Report date December 18, 2023 · Filed December 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,084 |
Reported balance
After 2023-12-18 transaction · row 1
1 source rowRow 1 · 2023-12-18 · Grant · Acquired 3,750 · Balance 17,084 F1: The Reporting person was awarded 3,750 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on June 1, 2024. |
| Common StockSEC Table I · non-derivative | IndirectBy Armanino Trust | 728,368 |
Reported balance
Holding disclosure · report date 2023-12-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 728,368 F2: These shares are owned directly by the Andrew J. Armanino III and Denise M. Armanino Family Trust (the "Armanino Trust", and directly by the Reporting Person and his spouse, Denise M. Armanino, as trustees of the Armanino Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting person was awarded 3,750 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on June 1, 2024.
F2: These shares are owned directly by the Andrew J. Armanino III and Denise M. Armanino Family Trust (the "Armanino Trust", and directly by the Reporting Person and his spouse, Denise M. Armanino, as trustees of the Armanino Trust.
California BanCorp \ CA
Report date August 20, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,704.41 |
Reported balance
After 2026-08-20 transaction · row 1
1 source rowRow 1 · 2026-08-20 · Grant · Acquired 1,025 · Balance 17,704.41 F1: Represents restricted stock units ("RSUs") issued to the Reporting Person as consideration for service on the Issuer's Board of Directors. Shares will be issued in full upon vesting, which is scheduled to occur on August 20, 2026. |
| Common StockSEC Table I · non-derivative | IndirectAndrew J Armanino & Denise M Armanino TR UA 6/2/1999 | 175,166 |
Reported balance
Holding disclosure · report date 2026-08-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 175,166 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") issued to the Reporting Person as consideration for service on the Issuer's Board of Directors. Shares will be issued in full upon vesting, which is scheduled to occur on August 20, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
California BanCorp
Report date July 31, 2024 · Filed July 31, 2024
Section 16 reporting ended · disclosed 2024-07-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-07-31 transaction · row 1
1 source rowRow 1 · 2024-07-31 · Disposition to issuer · Disposed 135,096 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger and Reorganization, dated January 31, 2024 (the "Merger Agreement"), by and between the Issuer and Southern California Bancorp ("BCAL"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger, each share of Issuer common stock converted into the right to receive 1.590 shares of BCAL common stock (the "Exchange Ratio"), with cash paid in lieu of fractional shares. As a result of the merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Issuer common stock. F2: Includes restricted stock units with respect to 1,399 shares of the Issuer's common stock. Pursuant to the Merger Agreement, at the effective time of the merger, the restricted stock units were assumed by BCAL and converted into a restricted stock units with respect to a number of shares of BCAL common stock equal to the number of issuer shares underlying the restricted stock unit multiplied by the Exchange Ratio. F3: This total amount corrects an administrative error in the total amount reported in previous filings. No reportable transaction was omitted from previously filings. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger and Reorganization, dated January 31, 2024 (the "Merger Agreement"), by and between the Issuer and Southern California Bancorp ("BCAL"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger, each share of Issuer common stock converted into the right to receive 1.590 shares of BCAL common stock (the "Exchange Ratio"), with cash paid in lieu of fractional shares. As a result of the merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Issuer common stock.
F2: Includes restricted stock units with respect to 1,399 shares of the Issuer's common stock. Pursuant to the Merger Agreement, at the effective time of the merger, the restricted stock units were assumed by BCAL and converted into a restricted stock units with respect to a number of shares of BCAL common stock equal to the number of issuer shares underlying the restricted stock unit multiplied by the Exchange Ratio.
F3: This total amount corrects an administrative error in the total amount reported in previous filings. No reportable transaction was omitted from previously filings.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2026 Filed Aug 25, 2026 00:00 UTC | California BanCorp \ CA BCAL · Entity 5250 | GrantCommon Stock | 1,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001807550-26-000008 · primarydocument.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,704.41 F1 · kind: Represents restricted stock units ("RSUs") issued to the Reporting Person as consideration for service on the Issuer's Board of Directors. Shares will be issued in full upon vesting, which is scheduled to occur on August 20, 2026. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:16 UTC | California BanCorp \ CA BCAL · Entity 5250 | GrantCommon Stock | 3,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001807550-26-000006 · primarydocument.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,679.41 F1 · kind: Represents restricted stock units ("RSUs") issued to the Reporting Person as consideration for service on the Issuer's Board of Directors. Shares will be issued in full upon vesting, which is scheduled to occur on June 1, 2027. Read SEC document |
| May 21, 2026 Filed May 26, 2026 17:03 UTC | California BanCorp \ CA BCAL · Entity 5250 | GrantCommon Stock | 1,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001807550-26-000004 · primarydocument.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,483.41 F1 · kind: Represents restricted stock units ("RSUs") issued to the Reporting Person as consideration for service on the Issuer's Board of Directors. Shares will be issued in full upon vesting, which is scheduled to occur on May 21, 2026. Read SEC document |
| February 20, 2026 Filed Feb 25, 2026 02:38 UTC | California BanCorp \ CA BCAL · Entity 5250 | GrantCommon Stock | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001807550-26-000002 · primarydocument.xml · nonDerivative · entry 2 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,443.41 F2 · kind: Represents restricted stock units ("RSUs") issued to the Reporting Person as consideration for service on the Issuer's Board of Directors. Shares will be issued in full upon vesting on February 20, 2026. Read SEC document |
| January 16, 2026 Filed Feb 25, 2026 02:38 UTC | California BanCorp \ CA BCAL · Entity 5250 | OtherCommon Stock | 40.41 | $18.89 | $763.34 |
DisclosureSEC source: 0001807550-26-000002 · primarydocument.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,401.41 F1 · kind: Reinvestment of cash dividends on January 16, 2026. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 19:42 UTC | California BanCorp \ CA BCAL · Entity 5250 | GrantCommon Stock | 1,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001807550-25-000003 · primarydocument.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,361 F1 · shares: Represents restricted stock units ("RSUs") issued to the Reporting Person as consideration for service on the Issuer's Board of Directors. Shares will be issued in full upon vesting on November 21, 2025. Read SEC document |
| August 21, 2025 Filed Aug 22, 2025 17:56 UTC | California BanCorp \ CA BCAL · Entity 5250 | GrantCommon Stock | 1,214 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005946 · primarydocument.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,313 F1 · shares: Represents restricted stock units ("RSUs") issued to the Reporting Person as consideration for service on the Issuer's Board of Directors. Shares will be issued in full upon vesting on August 21, 2025. Read SEC document |
| May 21, 2025 Filed May 23, 2025 23:46 UTC | California BanCorp \ CA BCAL · Entity 5250 | GrantCommon Stock | 3,729 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004159 · primarydocument.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,099 F1 · shares: Represents restricted stock units ("RSUs") issued to the Reporting Person as consideration for service on the Issuer's Board of Directors. Shares will be issued in full upon vesting, which is scheduled to occur on May 21, 2026. Read SEC document |
| August 08, 2024 Filed Aug 13, 2024 01:49 UTC | California BanCorp \ CA BCAL · Entity 5250 | GrantCommon Stock | 3,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-006174 · primarydocument.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,370 F1 · shares: Represents restricted stock units ("RSUs") issued to the Reporting Person as consideration for service on the Issuer's Board of Directors. Shares will be issued in full upon vesting, which is scheduled to occur on May 30, 2025. Read SEC document |
| July 31, 2024 Filed Jul 31, 2024 21:19 UTC | California BanCorp CALB · Entity 88623 | Disposition to issuerCommon Stock | 135,096 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-088708 · ownership.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger and Reorganization, dated January 31, 2024 (the "Merger Agreement"), by and between the Issuer and Southern California Bancorp ("BCAL"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger, each share of Issuer common stock converted into the right to receive 1.590 shares of BCAL common stock (the "Exchange Ratio"), with cash paid in lieu of fractional shares. As a result of the merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Issuer common stock. F2 · shares: Includes restricted stock units with respect to 1,399 shares of the Issuer's common stock. Pursuant to the Merger Agreement, at the effective time of the merger, the restricted stock units were assumed by BCAL and converted into a restricted stock units with respect to a number of shares of BCAL common stock equal to the number of issuer shares underlying the restricted stock unit multiplied by the Exchange Ratio. F3 · shares: This total amount corrects an administrative error in the total amount reported in previous filings. No reportable transaction was omitted from previously filings. F1 · price: Disposed of pursuant to the Agreement and Plan of Merger and Reorganization, dated January 31, 2024 (the "Merger Agreement"), by and between the Issuer and Southern California Bancorp ("BCAL"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger, each share of Issuer common stock converted into the right to receive 1.590 shares of BCAL common stock (the "Exchange Ratio"), with cash paid in lieu of fractional shares. As a result of the merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Issuer common stock. F2 · price: Includes restricted stock units with respect to 1,399 shares of the Issuer's common stock. Pursuant to the Merger Agreement, at the effective time of the merger, the restricted stock units were assumed by BCAL and converted into a restricted stock units with respect to a number of shares of BCAL common stock equal to the number of issuer shares underlying the restricted stock unit multiplied by the Exchange Ratio. Read SEC document |
| July 18, 2024 Filed Jul 22, 2024 23:27 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 1,399 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-085394 · ownership.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,626 F1 · shares: Represents annual grant of restricted stock units. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:30 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 482 | $24.89 | $11,996.98 |
DisclosureSEC source: 0000950170-24-011273 · ownership.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,227 F1 · shares: These shares were issued to the reporting person under the issuer's Amended and Restated 2017 Equty Incentive Plan in lieu of director retainer and meeting fees of $12,000. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 22:22 UTC | Better Therapeutics, Inc. BTTX · Entity 94385 | GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-071957 · ownership.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,084 F1 · shares: The Reporting person was awarded 3,750 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on June 1, 2024. Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 20:30 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 586 | $20.47 | $11,995.42 |
DisclosureSEC source: 0000950170-23-058275 · ownership.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,745 F1 · shares: These shares were issued to the reporting person under the issuer's Amended and Restated 2017 Equty Incentive Plan in lieu of director retainer and meeting fees of $12,000. Read SEC document |
| August 01, 2023 Filed Aug 18, 2023 20:30 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 645 | $18.60 | $11,997.00 |
DisclosureSEC source: 0000950170-23-043480 · ownership.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,777 F1 · shares: These shares were issued to the reporting person under the issuer's Amended and Restated 2017 Equty Incentive Plan in lieu of director retainer and meeting fees of $12,000. Read SEC document |
| July 27, 2023 Filed Jul 31, 2023 11:58 UTC | Better Therapeutics, Inc. BTTX · Entity 94385 | PurchaseCommon Stock | 274,010 | $0.73 | $199,999.90 |
DisclosureSEC source: 0000950170-23-035682 · ownership.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Armanino Trust Disclosed balance after: 728,368 F1 · kind: On July 25, 2023, the Issuer entered into a Securities Purchase Agreement with certain investors (the "PIPE Investors") in a private placement offering, pursuant to which the PIPE Investors agreed to purchase shares of Issuer common stock for $0.7299 per share. F2 · kind: As one of the PIPE Investors, the Reporting Person acquired 274,010 shares of Issuer common stock on July 27, 2023 for $0.7299 per share. F3 · ownership.nature: These shares are owned directly by the Andrew J. Armanino III and Denise M. Armanino Family Trust (the "Armanino Trust"), and directly by the Reporting Person and his spouse, Denise M. Armanino, as trustees of the Armanino Trust. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 22:56 UTC | Better Therapeutics, Inc. BTTX · Entity 94385 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0000950170-23-027336 · ownership.xml · derivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-06-06 F1 · derivative.exercise_date: The stock option vests in full on the earlier of the first anniversary of the grant date and the Issuer's next annual meeting of stockholders, provided that the Reporting Person continues to serve as a director of the Issuer on such vesting date. The stock option was granted on June 7, 2023. Read SEC document |
| May 18, 2023 Filed May 22, 2023 21:05 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 2,340 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-013582 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,132 F1 · shares: Annual grant of restricted stock units. Vests in full on May 16, 2024, subject to the reporting person's continuous service. Read SEC document |
| May 12, 2023 Filed May 15, 2023 21:23 UTC | California BanCorp CALB · Entity 88623 | PurchaseCommon Stock | 1,000 | $13.50 | $13,500.00 |
DisclosureSEC source: 0000899243-23-012973 · doc4.xml · nonDerivative · entry 3 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,792 Read SEC document |
| May 12, 2023 Filed May 15, 2023 21:23 UTC | California BanCorp CALB · Entity 88623 | PurchaseCommon Stock | 1,000 | $13.38 | $13,380.00 |
DisclosureSEC source: 0000899243-23-012973 · doc4.xml · nonDerivative · entry 2 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,792 Read SEC document |
| May 12, 2023 Filed May 15, 2023 21:23 UTC | California BanCorp CALB · Entity 88623 | PurchaseCommon Stock | 1,000 | $13.39 | $13,390.00 |
DisclosureSEC source: 0000899243-23-012973 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,792 Read SEC document |
| May 01, 2023 Filed May 4, 2023 00:28 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 725 | $16.57 | $12,013.25 |
DisclosureSEC source: 0000899243-23-012168 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,792 F1 · shares: These shares were issued to the reporting person under the issuer's Amended and Restated 2017 Equty Incentive Plan in lieu of director retainer and meeting fees. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 20:15 UTC | Better Therapeutics, Inc. BTTX · Entity 94385 | PurchaseCommon Stock | 303,030 | $0.83 | $249,999.75 |
DisclosureSEC source: 0000899243-23-011187 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Armanino Trust Disclosed balance after: 454,358 F1 · kind: On April 6, 2023, the Issuer entered into a Securities Purchase Agreement with certain investors (the "PIPE Investors") in a private placement offering, pursuant to which the PIPE Investors agreed to purchase shares of Issuer common stock for $0.825 per share. As one of the PIPE Investors, the Reporting Person acquired 303,030 shares of Issuer common stock on April 10, 2023 for $0.825 per share. F2 · balance_after: The Reporting Person no longer has a reportable beneficial interest in 15,000 shares of Issuer common stock owned by his son and included in the Reporting Person's prior ownership report on Form 4. F3 · ownership.nature: These shares are owned directly by the Andrew J. Armanino III and Denise M. Armanino Family Trust (the "Armanino Trust"), and indirectly by the Reporting Person and his spouse, Denise M. Armanino, as trustees of the Armanino Trust. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 22:04 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 471 | $25.47 | $11,996.37 |
DisclosureSEC source: 0000899243-23-003501 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,067 F1 · shares: These shares were issued to the reporting person under the issuer's Amended and Restated 2017 Equty Incentive Plan in lieu of director retainer and meeting fees of $12,000. Read SEC document |
| November 01, 2022 Filed Nov 18, 2022 01:05 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 541 | $22.22 | $12,021.02 |
DisclosureSEC source: 0000899243-22-036265 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,596 F1 · shares: These shares were issued to the reporting person under the issuer's Amended and Restated 2017 Equity Incentive Plan in lieu of director retainer and meeting fees of $12,000. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:19 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 567 | $21.18 | $12,009.06 |
DisclosureSEC source: 0000899243-22-027705 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,055 F1 · shares: These shares were issued to the reporting person under the issuer's Amended and Restated 2017 Equty Incentive Plan in lieu of director retainer and meeting fees of $12,000. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:31 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 1,538 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023381 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,488 F1 · shares: Represents annual grant of restricted stock units. The restricted stock units vest on May 18, 2023, subject to the reporting person's continuous service. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 23:11 UTC | Better Therapeutics, Inc. BTTX · Entity 94385 | PurchaseCommon Stock | 15,000 | $1.39 | $20,845.50 |
DisclosureSEC source: 0000899243-22-022912 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 15,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3850 to $1.3900, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:39 UTC | Better Therapeutics, Inc. BTTX · Entity 94385 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0000899243-22-021934 · doc4.xml · derivative · entry 3 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-08 F3 · derivative.exercise_date: The stock option vests in full on the earlier of the first anniversary of the grant date and the Issuer's next annual meeting of stockholders, provided that the Reporting Person continues to serve as a director of the Issuer on such vesting date. The stock option was granted on June 9, 2022. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:39 UTC | Better Therapeutics, Inc. BTTX · Entity 94385 | PurchaseCommon Stock | 25,000 | $1.65 | $41,355.00 |
DisclosureSEC source: 0000899243-22-021934 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Armanino Trust Disclosed balance after: 151,328 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.6475 to $1.6791, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: These shares are owned directly by the Andrew J. Armanino III and Denise M. Armanino Family Trust (the "Armanino Trust"), and indirectly by the Reporting Person and his spouse, Denise M. Armanino, as trustees of the Armanino Trust. Read SEC document |
| May 03, 2022 Filed May 5, 2022 20:00 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 552 | $21.74 | $12,000.48 |
DisclosureSEC source: 0000899243-22-016807 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,950 F1 · shares: These shares were issued to the Reporting Person under the issuer's Amended and Restated 2017 Equty Incentive Plan in lieu of retainer and meeting fees of $12,000. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 20:39 UTC | Better Therapeutics, Inc. BTTX · Entity 94385 | PurchaseCommon Stock | 40,000 | $2.14 | $85,620.00 |
DisclosureSEC source: 0000899243-22-012960 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Armanino Trust Disclosed balance after: 126,328 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.0882 to $2.2000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: These shares are owned directly by the Andrew J. Armanino III and Denise M. Armanino Family Trust (the "Armanino Trust"), and indirectly by the Reporting Person and his spouse, Denise M. Armanino, as trustees of the Armanino Trust. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:00 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 547 | $21.95 | $12,006.65 |
DisclosureSEC source: 0000899243-22-004559 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,398 F1 · shares: These shares were issued to the Reporting Person under the issuer's Amended and Restated 2017 Equty Incentive Plan in lieu of retainer and meeting fees of $12,000. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 21:45 UTC | Better Therapeutics, Inc. BTTX · Entity 94385 | PurchaseCommon Stock | 21,000 | $5.48 | $115,067.40 |
DisclosureSEC source: 0000899243-21-048370 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Armanino Trust Disclosed balance after: 86,328 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.4500 to $5.5000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: These shares are owned directly by the Andrew J. Armanino III and Denise M. Armanino Family Trust (the "Armanino Trust"), and indirectly by the Reporting Person and his spouse, Denise M. Armanino, as trustees of the Armanino Trust. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 21:42 UTC | Better Therapeutics, Inc. BTTX · Entity 94385 | PurchaseCommon Stock | 17,000 | $6.96 | $118,320.00 |
DisclosureSEC source: 0000899243-21-046418 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Armanino Trust Disclosed balance after: 65,328 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.93 to $6.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Reflects the correction of an immaterial error in Column 5 reported in the Reporting Person's Form 4 filed on November 1, 2021. F3 · ownership.nature: These shares are owned directly by the Andrew J. Armanino III and Denise M. Armanino Family Trust (the "Armanino Trust"), and indirectly by the Reporting Person and his spouse, Denise M. Armanino, as trustees of the Armanino Trust. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 18:29 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 663 | $18.12 | $12,013.56 |
DisclosureSEC source: 0000899243-21-043016 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,851 F1 · shares: These shares were issued to the Reporting Person under the issuer's Amended and Restated 2017 Equty Incentive Plan in lieu of retainer and meeting fees of $12,000. Read SEC document |
| October 28, 2021 Filed Nov 2, 2021 00:56 UTC | Better Therapeutics, Inc. BTTX · Entity 94385 | GrantStock Option (Right to Buy) · Derivative | 28,300 | $0.00 Strike: $10.97 | $0.00 |
DisclosureSEC source: 0000899243-21-042251 · doc4.xml · derivative · entry 3 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,300 Underlying: Common Stock · 28,300 shares Expires 2031-10-27 F4 · derivative.exercise_date: Following the Issuer's filing of Form S-8 to register the shares subject to the stock option, the stock option vests as to 1/3 of the shares subject to the stock option on October 28, 2022 and the remaining shares vest in 24 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The stock option was granted on October 28, 2021. Read SEC document |
| October 28, 2021 Filed Nov 2, 2021 00:56 UTC | Better Therapeutics, Inc. BTTX · Entity 94385 | GrantCommon Stock | 48,328 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042251 · doc4.xml · nonDerivative · entry 2 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Armanino Trust Disclosed balance after: 61,662 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated April 6, 2021, as amended (the "Merger Agreement"), by and among Mountain Crest Acquisition Corp. II ("Issuer"), MCAD Merger Sub Inc. ("Merger Sub") and Better Therapeutics, Inc. ("BTX"), on October 28, 2021, Merger Sub merged with and into BTX, with BTX surviving the merger as a wholly-owned subsidiary of Issuer (such merger and the other transactions contemplated by the Merger Agreement, the "Business Combination"). F2 · kind: At the effective time of the Business Combination, each share of BTX common stock (including shares of BTX common stock resulting from the conversion of BTX preferred stock and BTX Simple Agreements for Future Equity) was converted into a right to receive the number of shares of Issuer common stock equal to the product of the number of shares of BTX common stock and 0.9475, with fractional shares rounded to the nearest whole share. Issuer subsequently changed its name to Better Therapeutics, Inc. F1 · price: Pursuant to the Agreement and Plan of Merger, dated April 6, 2021, as amended (the "Merger Agreement"), by and among Mountain Crest Acquisition Corp. II ("Issuer"), MCAD Merger Sub Inc. ("Merger Sub") and Better Therapeutics, Inc. ("BTX"), on October 28, 2021, Merger Sub merged with and into BTX, with BTX surviving the merger as a wholly-owned subsidiary of Issuer (such merger and the other transactions contemplated by the Merger Agreement, the "Business Combination"). F2 · price: At the effective time of the Business Combination, each share of BTX common stock (including shares of BTX common stock resulting from the conversion of BTX preferred stock and BTX Simple Agreements for Future Equity) was converted into a right to receive the number of shares of Issuer common stock equal to the product of the number of shares of BTX common stock and 0.9475, with fractional shares rounded to the nearest whole share. Issuer subsequently changed its name to Better Therapeutics, Inc. F3 · ownership.nature: These shares are owned directly by the Andrew J. Armanino III and Denise M. Armanino Family Trust (the "Armanino Trust"), and indirectly by the Reporting Person and his spouse, Denise M. Armanino, as trustees of the Armanino Trust. Read SEC document |
| October 28, 2021 Filed Nov 2, 2021 00:56 UTC | Better Therapeutics, Inc. BTTX · Entity 94385 | GrantCommon Stock | 13,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042251 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,334 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated April 6, 2021, as amended (the "Merger Agreement"), by and among Mountain Crest Acquisition Corp. II ("Issuer"), MCAD Merger Sub Inc. ("Merger Sub") and Better Therapeutics, Inc. ("BTX"), on October 28, 2021, Merger Sub merged with and into BTX, with BTX surviving the merger as a wholly-owned subsidiary of Issuer (such merger and the other transactions contemplated by the Merger Agreement, the "Business Combination"). F2 · kind: At the effective time of the Business Combination, each share of BTX common stock (including shares of BTX common stock resulting from the conversion of BTX preferred stock and BTX Simple Agreements for Future Equity) was converted into a right to receive the number of shares of Issuer common stock equal to the product of the number of shares of BTX common stock and 0.9475, with fractional shares rounded to the nearest whole share. Issuer subsequently changed its name to Better Therapeutics, Inc. F1 · price: Pursuant to the Agreement and Plan of Merger, dated April 6, 2021, as amended (the "Merger Agreement"), by and among Mountain Crest Acquisition Corp. II ("Issuer"), MCAD Merger Sub Inc. ("Merger Sub") and Better Therapeutics, Inc. ("BTX"), on October 28, 2021, Merger Sub merged with and into BTX, with BTX surviving the merger as a wholly-owned subsidiary of Issuer (such merger and the other transactions contemplated by the Merger Agreement, the "Business Combination"). F2 · price: At the effective time of the Business Combination, each share of BTX common stock (including shares of BTX common stock resulting from the conversion of BTX preferred stock and BTX Simple Agreements for Future Equity) was converted into a right to receive the number of shares of Issuer common stock equal to the product of the number of shares of BTX common stock and 0.9475, with fractional shares rounded to the nearest whole share. Issuer subsequently changed its name to Better Therapeutics, Inc. Read SEC document |
| August 02, 2021 Filed Aug 20, 2021 18:36 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 672 | $17.86 | $12,001.92 |
DisclosureSEC source: 0000899243-21-033786 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,188 F1 · shares: These shares were issued to the Reporting Person under the issuer's Amended and Restated 2017 Equty Incentive Plan in lieu of retainer and meeting fees of $12,000. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 00:31 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 1,397 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-025153 · doc4.xml · nonDerivative · entry 2 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,188 F2 · shares: Represents restricted stock units that vest on June 30, 2022, subject to the Reporting Person's continuous service through the vesting date. Each restricted stock unit represents a contingent right to receive one share of Common Stock. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 00:31 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 671 | $17.89 | $12,004.19 |
DisclosureSEC source: 0000899243-21-025153 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,791 F1 · shares: These shares were issued to the Reporting Person under the issuer's Amended and Restated 2017 Equty Incentive Plan in lieu of retainer and meeting fees of $12,000. Read SEC document |
| January 28, 2021 Filed Feb 1, 2021 23:57 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 913 | $13.15 | $12,005.95 |
DisclosureSEC source: 0000899243-21-003892 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,025 F1 · price: These shares were issued to the reporting person under the issuer's Amended and Restated 2017 Equty Incentive Plan in lieu of retainer and meeting fees of $12,000. Read SEC document |
| November 03, 2020 Filed Nov 11, 2020 01:23 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 886 | $13.55 | $12,005.30 |
DisclosureSEC source: 0000899243-20-030755 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,112 F1 · price: These shares were issued to the reporting person under the issuer's Amended and Restated 2017 Equity Incentive Plan in lieu of retainer and meeting fees of $12,000. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 22:13 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 889 | $13.50 | $12,001.50 |
DisclosureSEC source: 0000899243-20-021914 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,448 F1 · price: These shares were issued to the reporting person under the issuer's 2017 Equty Incentive Plan in lieu of retainer and meeting fees of $12,000. Read SEC document |
| August 06, 2020 Filed Aug 19, 2020 23:24 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 1,852 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022952 · doc4.xml · nonDerivative · entry 2 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,226 F1 · shares: Represents restricted stock units that vest on June 30, 2021, subject to the Reporting Person's continuous service through the vesting date. Each restricted stock unit represents a contingent right to receive one share of Common Stock. Read SEC document |
| August 06, 2020 Filed Aug 19, 2020 23:24 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 926 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022952 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,374 Read SEC document |
| July 30, 2020 Filed Aug 3, 2020 21:05 UTC | California BanCorp CALB · Entity 88623 | PurchaseCommon Stock | 1,500 | $13.58 | $20,370.00 |
DisclosureSEC source: 0000899243-20-020998 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,559 Read SEC document |
| April 16, 2020 Filed Apr 20, 2020 19:28 UTC | California BanCorp CALB · Entity 88623 | GrantCommon Stock | 924 | $12.99 | $12,002.76 |
DisclosureSEC source: 0000899243-20-010978 · doc4.xml · nonDerivative · entry 1 Armanino Andrew J. · CIK 0001807550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,059 F1 · price: These shares were issued to the reporting person under the issuer's 2017 Equty Incentive Plan in lieu of retainer and meeting fees of $12,000. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.